Two Sigma Advisers LP Buys 24,100 Shares of Medpace Holdings, Inc. (NASDAQ:MEDP)

Two Sigma Advisers LP grew its stake in Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 12.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 212,500 shares of the company's stock after acquiring an additional 24,100 shares during the period. Two Sigma Advisers LP owned 0.68% of Medpace worth $70,599,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently modified their holdings of the company. Invesco Ltd. raised its position in Medpace by 91.8% in the 4th quarter. Invesco Ltd. now owns 1,084,753 shares of the company's stock worth $360,387,000 after purchasing an additional 519,186 shares during the last quarter. Proficio Capital Partners LLC increased its stake in shares of Medpace by 34,497.4% in the 4th quarter. Proficio Capital Partners LLC now owns 242,528 shares of the company's stock valued at $80,575,000 after buying an additional 241,827 shares during the period. Raymond James Financial Inc. acquired a new stake in shares of Medpace in the 4th quarter valued at $78,144,000. Norges Bank bought a new stake in shares of Medpace during the fourth quarter worth $69,859,000. Finally, GW&K Investment Management LLC lifted its stake in shares of Medpace by 93.9% during the fourth quarter. GW&K Investment Management LLC now owns 275,460 shares of the company's stock valued at $91,516,000 after acquiring an additional 133,379 shares during the period. 77.98% of the stock is currently owned by institutional investors and hedge funds.

Medpace Stock Performance

Shares of NASDAQ:MEDP opened at $305.98 on Tuesday. The company has a 50 day moving average price of $303.87 and a two-hundred day moving average price of $327.76. The company has a market capitalization of $8.79 billion, a PE ratio of 24.23, a PEG ratio of 3.81 and a beta of 1.55. Medpace Holdings, Inc. has a 52 week low of $250.05 and a 52 week high of $459.77.

Medpace (NASDAQ:MEDP - Get Free Report) last announced its quarterly earnings results on Monday, April 21st. The company reported $3.67 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.06 by $0.61. The company had revenue of $558.57 million during the quarter, compared to analyst estimates of $528.38 million. Medpace had a net margin of 19.17% and a return on equity of 51.48%. During the same quarter in the previous year, the business earned $3.20 EPS. On average, sell-side analysts forecast that Medpace Holdings, Inc. will post 12.29 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on MEDP shares. Truist Financial dropped their price objective on Medpace from $333.00 to $300.00 and set a "hold" rating for the company in a report on Wednesday, April 23rd. TD Cowen cut shares of Medpace from a "buy" rating to a "hold" rating and lowered their price target for the stock from $370.00 to $328.00 in a research report on Monday, April 14th. Robert W. Baird dropped their price target on shares of Medpace from $340.00 to $313.00 and set a "neutral" rating for the company in a research note on Wednesday, April 23rd. Leerink Partners initiated coverage on shares of Medpace in a research note on Monday, March 24th. They issued a "market perform" rating and a $330.00 price objective on the stock. Finally, Leerink Partnrs raised shares of Medpace to a "hold" rating in a report on Monday, March 24th. Eleven analysts have rated the stock with a hold rating and three have assigned a buy rating to the company's stock. According to MarketBeat, Medpace has a consensus rating of "Hold" and an average target price of $349.30.

Insiders Place Their Bets

In other news, Director Fred B. Davenport, Jr. sold 1,712 shares of Medpace stock in a transaction dated Thursday, April 24th. The stock was sold at an average price of $301.82, for a total transaction of $516,715.84. Following the transaction, the director now owns 2,998 shares in the company, valued at $904,856.36. The trade was a 36.35% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Corporate insiders own 20.30% of the company's stock.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.

Want to see what other hedge funds are holding MEDP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.